A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022

INTRODUCTION: The constantly mutating SARS-CoV-2 has been infected an increasing number of people, hence the safe and efficacious treatment are urgently needed to combat the COVID-19 pandemic. Currently, neutralizing antibodies (Nabs), targeting the receptor-binding domain (RBD) of the SARS-CoV-2 sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Kaikai, Liu, Bin, Yu, Haotian, Sun, Chengbiao, Wang, Xuefeng, Li, Guorui, Dong, Mingxin, Wang, Yan, Zhang, Jianxu, Xu, Na, Liu, Wensen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cellular and Infection Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189128/
https://www.ncbi.nlm.nih.gov/pubmed/37207187
http://dx.doi.org/10.3389/fcimb.2023.1155293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189128/
https://www.ncbi.nlm.nih.gov/pubmed/37207187
http://dx.doi.org/10.3389/fcimb.2023.1155293

Ejemplares similares